Nilesh Kumar, Ph.D.

Nilesh is partner at Novo Ventures and is based in Boston. In addition to Cirius, he also serves on boards of Tarveda, Morphic Therapeutics, Milestone Pharmaceuticals, Rgenix, Anokion and KanyosBio.

Prior to Novo, Nilesh was senior investment director at Merck and led investments in f-Star, RaNA (TranslateBio), Padlock, Auxogyn (Progyny). In addition of his venture role, Nilesh led several strategic licensing transactions for Merck Serono in field of oncology and autoimmune diseases. Nilesh received his Ph.D. and MBA from Harvard University, and undergraduate degree from University of Cambridge, UK.